Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Eric Lim, MD, of the Royal Brompton & Harefield NHS Foundation Trust, London, UK, discusses the Mesothelioma and Radical Surgery 2 (MARS2; NCT02040272) trial, which is investigating whether pleurectomy/decortication confers a survival advantage. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.